Sexual Health & Libido — Peptide Research Overview
Sexual dysfunction encompasses reduced libido, erectile dysfunction, arousal disorders, and anorgasmia. Several melanocortin-pathway peptides have been studied specifically for centrally-mediated sexual desire — a mechanism distinct from phosphodiesterase inhibitors which address vascular function only.
Relevant Compounds
- PT-141 (Bremelanotide) — MC4R agonist. FDA-approved for hypoactive sexual desire disorder in premenopausal women (Vyleesi). Studied in men for erectile dysfunction.
- Kisspeptin-10 — Hypothalamic neuropeptide that drives GnRH release and modulates sexual reward circuitry. Studied for psychosexual dysfunction.
- Melanotan II — Non-selective melanocortin agonist. Precursor to PT-141. Potent sexual arousal effects documented in human trials; not FDA-approved due to side effect profile.
What the Research Shows
PT-141 (Bremelanotide)
[Human Trial] PT-141 is FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women, based on two Phase 3 RCTs. In men with erectile dysfunction, Phase 2 trials showed significant improvement in erectile response even in patients who did not respond to sildenafil — supporting a central (brain-mediated) rather than peripheral mechanism. It acts on MC3R and MC4R in the hypothalamus.
Kisspeptin-10
[Human Trial — Preliminary] Kisspeptin drives GnRH pulsatility, which in turn stimulates LH and FSH. Human studies at Imperial College London show IV kisspeptin-54 enhances sexual brain processing (limbic/hypothalamic activation on fMRI) and reduces psychosexual dysfunction in patients with sexual aversion. Intranasal formulations are under investigation.
Melanotan II
[Human Trial — Phase 1/2] Early clinical trials at the University of Arizona demonstrated potent sexual arousal in men with erectile dysfunction, with erections occurring spontaneously at doses of 0.025 mg/kg. Not pursued to approval due to nausea, blood pressure changes, and tanning as side effects at effective doses. PT-141 was developed as a more selective, better-tolerated derivative.
Evidence Summary
| Compound | Evidence Level | FDA Status |
|---|---|---|
| PT-141 | Human Trial (Phase 3) | Approved (Vyleesi — women); off-label for men |
| Kisspeptin-10 | Human Trial (Preliminary) | Not approved |
| Melanotan II | Human Trial (Phase 1/2) | Not approved |
Research Disclaimer
PT-141 is FDA-approved for HSDD in premenopausal women only. No other compound listed on this page is FDA-approved for sexual health or libido. This page is an educational summary of existing research. Consult your healthcare provider before using any peptide or experimental compound.
Track your compounds with Dosi
Log doses, monitor symptoms, and build a personal health timeline. Free to start.
Start Tracking Free →Educational use only. This content is for informational purposes only and does not constitute medical advice. Individual results vary. Always consult a licensed healthcare provider before starting any compound.